Abstract:The rapidly rising incidence of obesity, coupled with type 2 diabetes mellitus (T2DM), is a growing concern. Glucagon-like peptide-1 (GLP-1), an endogenous peptide secreted by enteroendocrine L-cells, demonstrates exceptional pharmacological potential for the treatment of T2DM and obesity. Considering its proven efficacy in glucoregulation and weight loss, GLP-1 receptor agonists (GLP-1RAs) have emerged as a revolutionary breakthrough in the arena of diabetes management and weight control. Additional gastrointestinal hormones, such as glucose-dependent insulinotropic peptide (GIP) and glucagon, exhibit structural similarities to GLP-1 and work synergistically to lower blood glucose levels or aid in weight loss. Today, various classes of gut hormone receptor multiple agonists are steadily progressing through development and clinical trials, including dual GLP-1/glucagon receptor agonists, dual GLP-1/GIP receptor agonists, and triple GLP-1/GIP/glucagon receptor agonists. The GLP-1/GIP receptor co-agonist, tirzepatide, was approved by the US Food and Drug Administration (FDA) for the treatment of T2DM, outperforming basal insulin or selective GLP-1RAs by providing superior HbA1c reductions. Remarkably, tirzepatide also facilitated unprecedented weight loss of up to 22.5% in non-diabetic individuals living with obesity. This result is comparable to those achieved with certain types of bariatric surgery. Therefore, the advent of gut hormone multi-agonists signifies the dawn of an exciting new era in peptide-based therapy for obesity and T2DM. This review offers a comprehensive summary of the various types of gut hormone multiple agonists, including their discovery, development, action of mechanisms, and clinical effectiveness. We further delve into potential hurdles, limitations, and prospective advancements in the field.

Designer GLP1 poly-agonist peptides in the management of diabesity

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges

An Overview of New GLP-1 Receptor Agonists for Type 2 Diabetes

[A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists]

Recent advances in peptide-based therapies for obesity and type 2 diabetes

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

An update on peptide-based therapies for type 2 diabetes and obesity

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

Pharmacotherapy for Type 2 Diabetes Mellitus: What’s Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes

Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity